Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF -3.71%26 3-Year EBITDA Growth Rate is 7.60% as of Jun. 2026, which is 41% above its 10-year median of 5.40. GuruFocus rates CRDF with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 1,129 Biotechnology companies, Cardiff Oncology ranks worse than 58.64% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 40.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cardiff Oncology was 73.20% per year. The lowest was -51.10% per year. And the median was 5.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cardiff Oncology 3-Year EBITDA Growth Rate Related Terms
CRDF vs MNOV, PMVP, CING: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Cardiff Oncology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.60% mean?
Cardiff Oncology (CRDF) has a 3-Year EBITDA Growth Rate of 7.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardiff Oncology and its competitors. This is 41% above median its historical median of 5.40. According to the industry distribution chart, Cardiff Oncology ranks #662 out of 1129 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Cardiff Oncology's 3-Year EBITDA Growth Rate too high?
Cardiff Oncology's current 3-Year EBITDA Growth Rate of 7.60% is 41% above median its 10-year median of 5.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Cardiff Oncology's value of 7.60% is 48.3% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #662 out of 1129 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's 3-Year EBITDA Growth Rate compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #662 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Cardiff Oncology in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.70. Cardiff Oncology's value of 7.60% is 48.3% below this benchmark. While the company's 10-year median is 5.40 vs. the industry median of 14.70, Cardiff Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current 3-Year EBITDA Growth Rate of 7.60% is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardiff Oncology and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current 3-Year EBITDA Growth Rate is 7.60%, which is 41% above median its own 10-year median of 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current 3-Year EBITDA Growth Rate of 7.60%. The current 3-Year EBITDA Growth Rate is 7.60%, which is 41% above median its 10-year median of 5.40 and 48.3% below the Biotechnology industry median of 14.70. Cardiff Oncology's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current 3-Year EBITDA Growth Rate is 7.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
26GF Score
Get the complete analysis for CRDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
